Scilex Holding (SCLX) EBITDA (2020 - 2026)
Scilex Holding (SCLX) posted quarterly EBITDA of -$32.2 million for Q1 2026, down 15.31% year-over-year from -$38.0 million in Q1 2025, and up 19.45% on a QoQ basis from -$39.9 million in Q4 2025.
Scilex Holding (SCLX) EBITDA (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported EBITDA for 7 consecutive years, with -$32.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 15.31% year-over-year to -$32.2 million; the TTM figure through Mar 2026 stood at -$376.9 million (down 438.41% YoY), while the FY2025 annual figure was -$370.9 million, down 457.76% from the prior year.
- EBITDA came in at -$32.2 million for Q1 2026 at Scilex Holding, up from -$39.9 million in the prior quarter.
- The five-year high for EBITDA was -$1.2 million in Q3 2024, with the low at -$260.8 million in Q3 2025.
- Average EBITDA over 5 years is -$36.8 million, with a median of -$25.5 million recorded in 2023.
- Across the five-year window, EBITDA surged 96.54% in 2024 and sank 21136.97% in 2025, its largest moves.
- Year by year, EBITDA stood at -$19.7 million in 2022, then declined by 8.4% to -$21.4 million in 2023, then surged by 75.92% to -$5.2 million in 2024, then sank by 674.85% to -$39.9 million in 2025, then rose by 19.45% to -$32.2 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$32.2 million, -$39.9 million, and -$260.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 9.50 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 6.36 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.99 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 2.71 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -32.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.17 Mn |
| Dec 31, 2025 | -39.94 Mn |
| Sep 30, 2025 | -260.79 Mn |
| Jun 30, 2025 | -44.05 Mn |
| Mar 31, 2025 | -27.90 Mn |
| Dec 31, 2024 | -5.15 Mn |
| Sep 30, 2024 | -1.23 Mn |
| Jun 30, 2024 | -35.73 Mn |
| Mar 31, 2024 | -19.48 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -35.53 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -25.47 Mn |
| Dec 31, 2022 | -19.74 Mn |
| Sep 30, 2022 | -10.62 Mn |
| Jun 30, 2022 | -11.47 Mn |
| Mar 31, 2022 | -8.81 Mn |
| Dec 31, 2021 | -35.22 Mn |
| Sep 30, 2021 | -283,346.00 |
| Jun 30, 2021 | -172,140.00 |